MariMed Inc. (OTCMKTS:MRMD) Short Interest Update

MariMed Inc. (OTCMKTS:MRMD) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 37,428 shares, an increase of 271.6% from the November 30th total of 10,071 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,872,286 shares, the short-interest ratio is presently 0.0 days. Based on an average daily trading volume, of 2,872,286 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

MRMD has been the subject of a number of research reports. Zacks Research cut MariMed from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 11th. Ventum Cap Mkts downgraded MariMed from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

MariMed Stock Performance

OTCMKTS:MRMD traded down $0.00 during mid-day trading on Thursday, hitting $0.10. 618,158 shares of the company traded hands, compared to its average volume of 1,911,599. The company has a quick ratio of 0.35, a current ratio of 1.06 and a debt-to-equity ratio of 1.34. The stock’s fifty day moving average price is $0.11 and its 200-day moving average price is $0.11. The firm has a market cap of $37.58 million, a price-to-earnings ratio of -2.38 and a beta of 1.02. MariMed has a one year low of $0.07 and a one year high of $0.23.

MariMed (OTCMKTS:MRMD) last released its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). MariMed had a negative net margin of 11.36% and a negative return on equity of 14.67%. The company had revenue of $40.76 million during the quarter, compared to analyst estimates of $42.15 million.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.